Insmed01 / 11
Count us in.

EMEA Strategy Review

August, 2026

Insmed02 / 11

Recommend to right size EMEA organization to reflect the foreseeable opportunity

  • Most Favored Nation (MFN) policy exacerbates a deteriorating European environment for innovative pharmaceuticals
  • EMEA contributes <5% of total company NPV ($1.3B of $36.9B) but does carry strategic value in KOL relationships, clinical trial access, and regulatory presence
  • Under current structure, financial break-even achievable by 2032 with GTx (not probability adjusted) or 2034 (ARIKAYCE & BRINSUPRI only) – does not account for MFN impact on US & Japan
  • Unique gene therapy commercialization structure could be built later, if warranted
$36.9BTotal NPV

EMEA: 3.5% ($1.3B)

Rest of Company: 96.5% ($35.6B)

All figures reflect preliminary thinking & assumptions; to be confirmed

Insmed03 / 11

EMEA is currently over-sized for the realizable opportunity.“Lean promotion” provides most favorable EBITDA

EMEA Organization

~166 FTEs & $95 MM OPEX

Global Clin Ops and Tech Ops

~51 FTEs & ~$25 MM annual OPEX

EMEA commercialisation engine

~ 115 FTEs & ~$70 MM annual OPEX

Continued commercialization options improve EBITDA

Option 1Product availability, no promotion
Option 2Product availability, lean promotion

All figures reflect preliminary thinking & assumptions; to be confirmed

Insmed04 / 11

A lean, targeted commercial effort in EMEA improves EBITDA while supporting patient access to Insmed’s medicines

Recommended approach…

  • Ongoing global Tech Ops and Clin Ops/Trials support
  • Targeted promotion of Arikayce and Brinsupri in select markets

Preliminary Assessment led by Neil…

  • EMEA organisation reduced by around 70 FTEs
  • Total OPEX halved
  • 4 year EBITDA improved >$180M
  • Arikayce revenues assumed to decrease ~ $12 MM over 4 years (assumes no Brinsupri reimbursement)
  • Restructuring costs estimated at ~$5 – 10 MM1
Updated Europe Map

All figures reflect preliminary thinking & assumptions; to be confirmed
1. Initial Estimate to be confirmed depending on severance package, # impacted employees, etc

Insmed05 / 11

Key trade offs: Reputational & cultural risk, reduced influence with medical community; recommend proceeding

Key risks of exit include cultural hit, corporate reputation, loss of KOL relationships, clinical trial recruitment impact, ceding first-mover advantage to competitors

Next Steps: Review EMEA team recommendation & assumptions, refine analysis, develop implementation and communication plan

Insmed06 / 11

Supporting Documents – Pre-Read only

Insmed07 / 11

Cumulative break-even in 2032 mainly supported by significant revenue contribution from GTx

USDm
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
Total
Revenue
Arikayce
32
33
34
34
35
33
33
32
32
32
32
363
Brinsupsi
2
17
19
57
97
134
162
188
213
237
255
1,381
TPIP
-
-
-
-
-
17
37
50
66
84
103
357
GTx Total
-
-
-
-
6
109
678
719
1,170
1,250
1,309
5,241
Total Net Sales
34
50
53
92
137
293
909
989
1,481
1,603
1,700
7,341
Total COGS
-11
-13
-14
-22
-31
-62
-185
-200
-297
-318
-333
-1,487
Gross margin
24
37
39
70
106
231
724
789
1,184
1,285
1,366
5,855
Margin
69%
74%
73%
76%
78%
79%
80%
80%
80%
80%
80%
80%
G&A
19
22
25
27
30
34
35
36
36
37
37
337
S&M
40
45
59
68
86
134
146
149
145
146
145
1,163
R&D
28
33
42
53
63
83
87
89
91
96
98
761
Tech Ops
3
3
3
3
3
4
4
5
5
5
5
42
Total costs
89
103
129
150
183
254
273
279
277
283
285
2,304
EBITDA
-65.3
-66.2
-89.7
-80
-76.2
-23.0
450.8
510.2
907.3
1,001.9
1,081.2
3,551
as % of net sales
-191%
-134%
-168%
-87%
-56%
-8%
50%
52%
61%
63%
64%
48%
Insmed08 / 11

ARIKAYCE & BRINSUPRI only cumulative break-even in 2034

Represents cumulative break-even

Net Sales
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
Germany
$10
$24
$19
$30
$38
$46
$53
$60
$66
$72
UK
7
7
9
14
20
25
33
39
49
57
France
5
5
5
5
5
4
4
4
4
4
Italy
2
2
3
10
18
25
25
27
31
35
Spain
0
0
2
10
19
26
30
34
32
32
All other countries
11
12
16
23
32
40
47
55
62
69
Total EMEA
$34
$50
$53
$92
$132
$167
$194
$220
$245
$269
EBITDA
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
Germany
($22)
($20)
($26)
($14)
($7)
$10
$18
$26
$34
$39
UK
(3)
(6)
(8)
(4)
1
2
9
16
27
34
France
(3)
(4)
(3)
(2)
(1)
(1)
(0)
1
1
1
Italy
(6)
(11)
(15)
(12)
(6)
3
5
7
12
16
Spain
(5)
(7)
(10)
(4)
3
9
12
17
16
16
All other countries
(5)
(6)
(6)
(2)
4
8
15
23
29
35
Total EMEA
($44)
($53)
($67)
($38)
($5)
$31
$58
$90
$120
$141

G&A costs have not been allocated to the individual countries; All other infrastructure costs are included

Insmed09 / 11

BRINSUPRI avg net price estimated <$10K, declining to ~$8K

At LaunchBy mid-2030s
Germany1$9,360$9,360
UK8,7556,511
Italy7,6054,106
Spain7,6055,780
Austria114,8499,360
Switzerland110,98010,980
Netherlands8,7758,775
Portugal8,7758,775
Average$9,588$7,956

1. Prices represent direct pricing. (team is proposing import model initially)

Insmed10 / 11

Cumulative P&L (2027-2030): Lean organization with product promotion provides the most favourable EBITDA

Incremental only
# in USDm
Current, FY27-30
Global Support Only
Product Supply & no promotion
Product supply and promotion
Product Supply & no promotion
Product supply and promotion
Total Net Sales
190
0
111
178
111
178
Total COGS
-53
0
-32
-51
-32
-51
Gross Margin
137
0
79
127
79
127
Margin
72%
-
71%
71%
71%
71%
Total OpEx
-377
-98
-143
-185
-46
-87
EBITDA
-240
-98
-64
-58
33
40
# FTEs
166
51
65
90
15
40

Potential savings of ~140m to ~180m

1. All figures reflect preliminary thinking & assumptions; to be confirmed
Note: COGS includes royalties expenses

Insmed11 / 11

FTEs breakdown by function across scenarios

Currently
Global support (no supply)
Product supply (no promotion)
Product supply & promotion
Sales and Marketing
59
0
7
28
Development
74
36
37
40
Clinical Development
1
1
1
1
Clinical Operations
13
13
13
13
Drug Safety & PV
4
2
2
2
Medical
34
9
9
12
Program Management
2
1
1
1
Quality Assurance
13
6
7
7
Regulatory Affairs
7
4
4
4
G&A
27
12
17
18
TechOps (Logistics)
6
3
5
5
Total
166
51
65
90
-115/-70%

Commercial -59, Medical -25, G&A -15, QA -7, Others -9

+15

Commercial +7, QA + Supply +3 G&A +5

+25

Commercial +21, Medical +3, G&A +1

1. All figures reflect preliminary thinking & assumptions; to be confirmed